{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:44:20Z","timestamp":1783943060042,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Marie Sk\u0142odowska-Curie grant agreement","award":["847551"],"award-info":[{"award-number":["847551"]}]},{"name":"Marie Sk\u0142odowska-Curie grant agreement","award":["847551"],"award-info":[{"award-number":["847551"]}]},{"name":"AMC Innovation Grant"},{"name":"NWO ZonMW VENI","award":["09150161810112"],"award-info":[{"award-number":["09150161810112"]}]},{"name":"FOREUM Foundation for Research in Rheumatology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03638-0","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:45:32Z","timestamp":1762343132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dual impact of interleukin-17\u00a0A blockade on inflammatory and stromal pathways in peripheral spondyloarthritis"],"prefix":"10.1186","volume":"27","author":[{"given":"Ihsan","family":"Hammoura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e H.","family":"Fiechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonieke J. J.","family":"van Mens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri\u00ebtte M. Y.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inka A.","family":"Fluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander W.","family":"Tas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique L.P.","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen G.H.","family":"van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya G.","family":"Yeremenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"6","key":"3638_CR1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Van Der Heijde D, Landew\u00e9 R, Listing J, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3638_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Akkoc N, Brandt J, Chou C, et al. The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"3638_CR3","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"10163","key":"3638_CR4","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Wei JC-C, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441\u201351.","journal-title":"Lancet"},{"issue":"10217","key":"3638_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, Kim T-H, Maksymowych WP, \u00d8stergaard M, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53\u201364.","journal-title":"Lancet"},{"issue":"6","key":"3638_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72(6):815\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3638_CR7","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","volume":"75","author":"WP Maksymowych","year":"2016","unstructured":"Maksymowych WP, Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, et al. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Ann Rheum Dis. 2016;75(7):1328\u201335.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3638_CR8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.40866","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landew\u00e9 R, et al. A fifty-two\u2013week, randomized, placebo\u2010controlled trial of certolizumab Pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(7):1101\u201311.","journal-title":"Arthritis Rheumatol"},{"issue":"14","key":"3638_CR9","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, Van Der Heijde D, et al. Secukinumab Inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"issue":"4","key":"3638_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"issue":"1","key":"3638_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3638_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and safety of Ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen\u2010week results from a phase III randomized, double\u2010blind, placebo\u2010controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599\u2013611.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"3638_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/art.40770","volume":"71","author":"MN van Tok","year":"2019","unstructured":"van Tok MN, van Duivenvoorde LM, Kramer I, Ingold P, Pfister S, Roth L, et al. Interleukin-17A Inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis. Arthritis Rheumatol. 2019;71(4):612\u201325.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"3638_CR14","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, et al. Effect of Secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76(6):1070\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"3638_CR15","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1093\/rheumatology\/kez684","volume":"59","author":"V Chandran","year":"2020","unstructured":"Chandran V, van der Heijde D, Fleischmann RM, Lespessailles E, Helliwell PS, Kameda H, et al. Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology. 2020;59(10):2774\u201384.","journal-title":"Rheumatology"},{"issue":"12","key":"3638_CR16","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/art.40581","volume":"70","author":"LJ van Mens","year":"2018","unstructured":"van Mens LJ, van de Sande MG, Menegatti S, Chen S, Blijdorp IC, de Jong HM, et al. Brief report: interleukin-17 Blockade with Secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses. Arthritis Rheumatol. 2018;70(12):1994\u20132002.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3638_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. EdgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139\u201340.","journal-title":"Bioinformatics"},{"issue":"3","key":"3638_CR18","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.xjidi.2021.100094","volume":"2","author":"J Liu","year":"2022","unstructured":"Liu J, Chang H-W, Grewal R, Cummins DD, Bui A, Beck KM, et al. Transcriptomic profiling of plaque psoriasis and cutaneous T-cell subsets during treatment with Secukinumab. JID Innovations. 2022;2(3):100094.","journal-title":"JID Innovations"},{"issue":"3","key":"3638_CR19","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","volume":"144","author":"JG Krueger","year":"2019","unstructured":"Krueger JG, Wharton KA Jr, Schlitt T, Suprun M, Torene RI, Jiang X, et al. IL-17A Inhibition by Secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750\u201363.","journal-title":"J Allergy Clin Immunol"},{"key":"3638_CR20","doi-asserted-by":"publisher","first-page":"611656","DOI":"10.3389\/fimmu.2021.611656","volume":"12","author":"RH Fiechter","year":"2021","unstructured":"Fiechter RH, De Jong HM, Van Mens LJ, Fluri IA, Tas SW, Baeten DL, et al. IL-12p40\/IL-23p40 Blockade with ustekinumab decreases the synovial inflammatory infiltrate through modulation of multiple signaling pathways including MAPK-ERK and Wnt. Front Immunol. 2021;12:611656.","journal-title":"Front Immunol"},{"issue":"4","key":"3638_CR21","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.3390\/ijms24044108","volume":"24","author":"LA Coletto","year":"2023","unstructured":"Coletto LA, Rizzo C, Guggino G, Caporali R, Alivernini S, D\u2019Agostino MA. The role of neutrophils in spondyloarthritis: A journey across the spectrum of disease manifestations. Int J Mol Sci. 2023;24(4):4108.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3638_CR22","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/rheumatology\/key375","volume":"58","author":"J Braun","year":"2019","unstructured":"Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha EM, et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology. 2019;58(5):859\u201368.","journal-title":"Rheumatology"},{"issue":"8","key":"3638_CR23","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/art.41271","volume":"72","author":"X Xu","year":"2020","unstructured":"Xu X, Davelaar N, Mus AM, Asmawidjaja PS, Hazes JM, Baeten DL, et al. Interleukin-17A is produced by CD4\u2009+\u2009but not CD8\u2009+\u2009T cells in synovial fluid following T cell receptor activation and regulates different inflammatory mediators compared to tumor necrosis factor in a model of psoriatic arthritis synovitis. Arthritis Rheumatol. 2020;72(8):1303\u201313.","journal-title":"Arthritis Rheumatol"},{"issue":"9999","key":"3638_CR24","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"6","key":"3638_CR25","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3638_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/annrheumdis-2020-218186","volume":"80","author":"A Nerviani","year":"2021","unstructured":"Nerviani A, Boutet M-A, Tan WSG, Goldmann K, Purkayastha N, Lajtos TA, et al. IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in Understanding clinical responses to IL-23 inhibitors. Ann Rheum Dis. 2021;80(5):591\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3638_CR27","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/art.38995","volume":"67","author":"J Belasco","year":"2015","unstructured":"Belasco J, Louie JS, Gulati N, Wei N, Nograles K, Fuentes-Duculan J, et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol. 2015;67(4):934\u201344.","journal-title":"Arthritis Rheumatol"},{"key":"3638_CR28","doi-asserted-by":"crossref","unstructured":"Ritchlin C, editor. Editor navigating the diverse immune landscapes of psoriatic arthritis. Seminars in immunopathology. Springer; 2021.","DOI":"10.1007\/s00281-021-00848-x"},{"issue":"10","key":"3638_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrd3794","volume":"11","author":"P Miossec","year":"2012","unstructured":"Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discovery. 2012;11(10):763\u201376.","journal-title":"Nat Rev Drug Discovery"},{"issue":"17","key":"3638_CR30","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.3390\/ijms21176401","volume":"21","author":"H Tsukazaki","year":"2020","unstructured":"Tsukazaki H, Kaito T. The role of the IL-23\/IL-17 pathway in the pathogenesis of spondyloarthritis. Int J Mol Sci. 2020;21(17):6401.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3638_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41584-018-0044-2","volume":"14","author":"LS Taams","year":"2018","unstructured":"Taams LS, Steel KJ, Srenathan U, Burns LA, Kirkham BW. IL-17 in the Immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol. 2018;14(8):453\u201366.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03638-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:45:34Z","timestamp":1762343134000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03638-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3638"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03638-0","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients have provided a written informed consent, and the study has received approval from the ethics board of the Academic Medical Center Amsterdam.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Declared Conflicts of Interest: M.G.H.v.d.S have received research support from Abbvie, Novartis, Janssen and UCB, consulting fees from Abbvie, Janssen, Novartis, UCB, and speaker fees from Benecke, Eli Lilly, Janssen, Novartis, UCB. All remaining authors declare that they have no conflicts of interest that might have influenced the work reported in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}